Literature DB >> 30190871

Biology and treatment of BRAF mutant metastatic melanoma.

Benjamin Y Kong1,1, Matteo S Carlino1,2,3,1,2,3, Alexander M Menzies2,3,4,2,3,4.   

Abstract

BRAF inhibitors were among the first systemic therapies to show clinical benefit in metastatic melanoma. Here, we review the spectrum of BRAF mutations in melanoma, their role in oncogenesis, clinicopathological associations and response to treatment. The differing biology and clinical features of V600E- and V600K-mutated melanoma are outlined. The molecular changes associated with BRAF fusion genes and their response to targeted therapies, as well as the role of immunotherapy in treatment sequencing with targeted therapies are discussed.

Entities:  

Keywords:  BRAF; BRAF fusion genes; V600E; V600K; dabrafenib; melanoma; mutation; trametinib; vemurafenib

Year:  2016        PMID： 30190871      PMCID： PMC6097549          DOI： 10.2217/mmt.15.38

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


  103 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

Review 2.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

3.  BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.

Authors:  Victoria J Mar; Stephen Q Wong; Jason Li; Richard A Scolyer; Catriona McLean; Anthony T Papenfuss; Richard W Tothill; Hojabr Kakavand; Graham J Mann; John F Thompson; Andreas Behren; Jonathan S Cebon; Rory Wolfe; John W Kelly; Alexander Dobrovic; Grant A McArthur
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

4.  Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.

Authors:  Angela J Sievert; Shih-Shan Lang; Katie L Boucher; Peter J Madsen; Erin Slaunwhite; Namrata Choudhari; Meghan Kellet; Phillip B Storm; Adam C Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

5.  MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Authors:  Nikhil Wagle; Eliezer M Van Allen; Daniel J Treacy; Dennie T Frederick; Zachary A Cooper; Amaro Taylor-Weiner; Mara Rosenberg; Eva M Goetz; Ryan J Sullivan; Deborah N Farlow; Dennis C Friedrich; Kristin Anderka; Danielle Perrin; Cory M Johannessen; Aaron McKenna; Kristian Cibulskis; Gregory Kryukov; Eran Hodis; Donald P Lawrence; Sheila Fisher; Gad Getz; Stacey B Gabriel; Scott L Carter; Keith T Flaherty; Jennifer A Wargo; Levi A Garraway
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

6.  Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.

Authors:  Nancy E Thomas; Sharon N Edmiston; Audrey Alexander; Robert C Millikan; Pamela A Groben; Honglin Hao; Dawn Tolbert; Marianne Berwick; Klaus Busam; Colin B Begg; Dianne Mattingly; David W Ollila; Chiu Kit Tse; Amanda Hummer; Julia Lee-Taylor; Kathleen Conway
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-05       Impact factor: 4.254

7.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

8.  Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.

Authors:  Piotr Rutkowski; Aleksandra Gos; Monika Jurkowska; Tomasz Switaj; Wirginiusz Dziewirski; Marcin Zdzienicki; Konrad Ptaszyński; Wanda Michej; Andrzej Tysarowski; Janusz A Siedlecki
Journal:  Oncol Lett       Date:  2014-05-08       Impact factor: 2.967

9.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.

Authors:  Michael Krauthammer; Yong Kong; Antonella Bacchiocchi; Perry Evans; Natapol Pornputtapong; Cen Wu; Jamie P. McCusker; Shuangge Ma; Elaine Cheng; Robert Straub; Merdan Serin; Marcus Bosenberg; Stephan Ariyan; Deepak Narayan; Mario Sznol; Harriet M Kluger; Shrikant Mane; Joseph Schlessinger; Richard P Lifton; Ruth Halaban
Journal:  Nat Genet       Date:  2015-07-27       Impact factor: 41.307

10.  Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

Authors:  A M Menzies; J S Wilmott; G V Long; R A Scolyer
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640
View more
  12 in total

1.  Sequential Treatment With Targeted and Immune Checkpoint Therapy in Patients With BRAF Positive Metastatic Melanoma: The Importance of Timing?

Authors:  Victoria Grätz; Detlef Zillikens; Hauke Busch; Ewan A Langan; Patrick Terheyden
Journal:  Front Med (Lausanne)       Date:  2019-12-17

2.  Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.

Authors:  Ewelina Dratkiewicz; Aleksandra Simiczyjew; Katarzyna Pietraszek-Gremplewicz; Justyna Mazurkiewicz; Dorota Nowak
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

3.  Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients.

Authors:  Lauren G Aoude; Vanessa F Bonazzi; Sandra Brosda; Kalpana Patel; Lambros T Koufariotis; Harald Oey; Katia Nones; Scott Wood; John V Pearson; James M Lonie; Melissa Arneil; Victoria Atkinson; B Mark Smithers; Nicola Waddell; Andrew P Barbour
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

4.  An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status.

Authors:  Manmeet Ahluwalia; Mir A Ali; Rushikesh S Joshi; Eun Suk Park; Birra Taha; Ian McCutcheon; Veronica Chiang; Angela Hong; Georges Sinclair; Jiri Bartek; Clark C Chen
Journal:  Neurooncol Adv       Date:  2020-11-12

Review 5.  Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma.

Authors:  Alessandro Nepote; Gianluca Avallone; Simone Ribero; Francesco Cavallo; Gabriele Roccuzzo; Luca Mastorino; Claudio Conforti; Luca Paruzzo; Stefano Poletto; Fabrizio Carnevale Schianca; Pietro Quaglino; Massimo Aglietta
Journal:  J Clin Med       Date:  2022-02-04       Impact factor: 4.241

6.  Genome-wide screening identifies novel genes implicated in cellular sensitivity to BRAFV600E expression.

Authors:  Tengyu Ko; Rahul Sharma; Shisheng Li
Journal:  Oncogene       Date:  2019-09-23       Impact factor: 9.867

7.  Low BRAF V600 mutation prevalence in primary skin nodular melanoma in Indonesia: a real-time PCR detection among Javanese patients.

Authors:  Hanggoro Tri Rinonce; Rovi Panji Mustiko Aji; Ni'mah Hayati; Maria Fransiska Pudjohartono; Bidari Kameswari
Journal:  BMC Proc       Date:  2019-12-16

8.  Real-world outcomes of advanced melanoma patients not represented in phase III trials.

Authors:  Michiel C T van Zeijl; Rawa K Ismail; Liesbeth C de Wreede; Alfonsus J M van den Eertwegh; Anthonius de Boer; Maaike van Dartel; Doranne L Hilarius; Maureen J B Aarts; Franchette W P J van den Berkmortel; Marye J Boers-Sonderen; Jan-Willem B de Groot; Geke A P Hospers; Ellen Kapiteijn; Djura Piersma; Rozemarijn S van Rijn; Karijn P M Suijkerbuijk; Albert J Ten Tije; Astrid A M van der Veldt; Gerard Vreugdenhil; John B A G Haanen; Michel W J M Wouters
Journal:  Int J Cancer       Date:  2020-07-04       Impact factor: 7.316

9.  Atypical UV Photoproducts Induce Non-canonical Mutation Classes Associated with Driver Mutations in Melanoma.

Authors:  Marian F Laughery; Alexander J Brown; Kaitlynne A Bohm; Smitha Sivapragasam; Haley S Morris; Mila Tchmola; Angelica D Washington; Debra Mitchell; Stephen Mather; Ewa P Malc; Piotr A Mieczkowski; Steven A Roberts; John J Wyrick
Journal:  Cell Rep       Date:  2020-11-17       Impact factor: 9.423

10.  A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.

Authors:  Kevin Yao; Emily Zhou; Chao Cheng
Journal:  Cancer Med       Date:  2022-01-19       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.